Tsukamura M
Jpn J Antibiot. 1975 Apr;28(2):143-8.
Therapeutic effect of lividomycin was observed in patients with infections of the respiratory tract (infections in association with bronchiectasis, mixed infections of cavities after negative conversion of tubercle bacilli, pneumonia, and so forth). Significant improvement of clinical symptoms was observed in 15 cases and no improvement in 4 cases. Lividomycin was administered at a dose of 1 g/day for 3 to 15 days. Staphylococcus aureus (9 cases), Klebsiella pneumoniae (1 case), alpha-hemolytic Streptococcus (3 cases), Aerococcus (4 cases) and Pseudomonas aeruginosa (1 case) were suggested to be causative organisms in the above-mentioned patients. (In one case, however, causative organism was not determined.) Lividomycin seemed to be effective in cases of infections with Staphylococcus aureus, alpha-hemolytic Streptococcus and Klebsiella pneumoniae, whereas not effective in a case of infection with Pseudomonas aeruginosa. In order to differentiate causative organisms from the organisms constantly existing on the upper respiratory tract, alkali treatment was employed as an aid for the determination of the causative organisms. However, further studies are desirable for the evaluation of this procedure.
观察了青紫霉素对呼吸道感染患者(支气管扩张合并感染、结核菌转阴后空洞混合感染、肺炎等)的治疗效果。15例患者临床症状明显改善,4例无改善。青紫霉素给药剂量为每日1g,疗程3至15天。上述患者的致病菌提示为金黄色葡萄球菌(9例)、肺炎克雷伯菌(1例)、α溶血性链球菌(3例)、气球菌(4例)和铜绿假单胞菌(1例)。(然而,有1例未确定致病菌。)青紫霉素似乎对金黄色葡萄球菌、α溶血性链球菌和肺炎克雷伯菌感染有效,而对铜绿假单胞菌感染无效。为了将致病菌与上呼吸道中经常存在的微生物区分开来,采用碱处理辅助确定致病菌。然而,对于该方法的评估还需要进一步研究。